Press release - May 12th, 2011

Expanding competences: cerbomed GmbH gains Prof. Dr. Barry R. Komisaruk for its scientific advisory board.

ERLANGEN, Germany, 12.05.2011 – cerbomed GmbH, the medical device company, has gained Prof. Dr. Barry R. Komisaruk for its scientific advisory board. Prof. Dr. Komisaruk, from New Jersey, USA, is an expert in the vegetative nervous system and the functional imaging of the brainstem. He will work with cerbomed GmbH on a study into the working mechanism of transcutaneous vagus nerve stimulation (t- VNS).

Joint research for promising therapeutic approaches
"I am very much looking forward to the study with cerbomed GmbH. t-VNS shows promising signs for the effective stimulation of specific brain regions. This can bring us new understanding of the signal processing in the vegetative nervous system", says Prof. Dr. Komisaruk.
Prof. Dr. Komisaruk is Professor II of Psychology and Associate Dean of the Graduate School at Rutgers State University in New Jersey. He has years of experience in animal and human experimental studies, and is a respected expert in the functional imaging of the brainstem.
One of the main emphases of his current research is in functional neuroimaging to support the examination of the vegetative nervous system of patients with damage to the spinal cord.

"Prof. Dr. Komisaruk is an outstanding expert in the imaging of the brainstem. His long-standing experience makes it possible for us to carry out a pioneering translational human study investigating the mode of action of t-VNS", says Prof. Dr. Jens Ellrich, Chief Medical Officer at cerbomed GmbH.

About t-VNS
t-VNS is applied to the left outer ear, over the auricular branch of the vagus nerve, where it stimulates the nerve transcutaneously. Cerbomed therefore expects t-VNS to offer a highly attractive and cost-effective alternative to current and emerging VNS treatments, other neurostimulation methods, surgery or pharmacologic therapies.

About cerbomed
Cerbomed is a privately held, medical device company based in Erlangen, Germany, aiming to become the leader for the development of non-invasive Vagus Nerve Stimulation (VNS) therapies. The company was founded in 2005 to develop and commercialize its proprietary, transcutaneous Vagus Nerve Stimulation (t-VNS) technology and devices for therapeutic uses. NEMOS products comprise the world’s first non-invasive VNS device enabling specific electrical brain stimulation. The company has received a CE-mark for NEMOS in Europe.

Cerbomed GmbH is present as an exhibitor for the first time at the 10th world congress of the International Neuromodulation Society from May 21st to 26th in London. At this international convention t-VNS will also be introduced in a poster and a classroom session.

pdf Download Article

Please note: NEMOS® is not cleared or approved for use in the U.S.